Cargando…

Molecular and immune heterogeneity in synchronous melanoma metastases

Detalles Bibliográficos
Autores principales:	Reuben, Alexandre, Spencer, Christine, Roszik, Jason, Miller, John, Kwong, Lawrence, Jiang, Hong, Haymaker, Cara, Chen, Pei-Ling, Austin-Breneman, Jacob, Roh, Whijae, Little, Latasha, Cao, Yu, Garber, Haven, Forget, Marie-Andrée, Gopalakrishnan, Vancheswaran, Amaria, Rodabe, Davies, Michael, Bernatchez, Chantale, Roger, Edwin, Cuentas, Parra, Rodriguez, Jaime, Tetzlaff, Michael, Woodman, Scott, Dwyer, Karen, Sharma, Padmanee, Allison, James, Chin, Lynda, Futreal, Andrew, Cooper, Zachary, Wargo, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649346/ http://dx.doi.org/10.1186/2051-1426-3-S2-P262

Ejemplares similares

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
por: Reuben, Alexandre, et al.
Publicado: (2017)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
por: Qin, Yong, et al.
Publicado: (2017)

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
por: Cooper, Zachary A., et al.
Publicado: (2016)

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes
por: Haymaker, Cara, et al.
Publicado: (2015)

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015)

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes
por: Forget, Marie-Andrée, et al.
Publicado: (2017)

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy
por: Andrews, Miles C., et al.
Publicado: (2018)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Linking Associations of Rare Low-Abundance Species to Their Environments by Association Networks
por: Karpinets, Tatiana V., et al.
Publicado: (2018)

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity
por: Malu, Shruti, et al.
Publicado: (2013)

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
por: McKenzie, Jodi A, et al.
Publicado: (2017)

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells
por: Haymaker, Cara, et al.
Publicado: (2013)

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
por: Parra, Edwin R., et al.
Publicado: (2017)

PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012)

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
por: Roszik, Jason, et al.
Publicado: (2016)

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity
por: Forget, Marie-Andrée, et al.
Publicado: (2015)

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
por: Haymaker, Cara L, et al.
Publicado: (2015)

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
por: Uemura, Marc, et al.
Publicado: (2016)

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity
por: Punt, Simone, et al.
Publicado: (2020)

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
por: Mitra, Akash, et al.
Publicado: (2020)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
por: Pelster, Meredith S., et al.
Publicado: (2019)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
por: Tetzlaff, Michael T., et al.
Publicado: (2018)

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2016)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2017)

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
por: Burton, Elizabeth M., et al.
Publicado: (2022)

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
por: Glitza, Isabella C, et al.
Publicado: (2018)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Sloane, Robert A. Szczepaniak, et al.
Publicado: (2021)

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
por: Fix, Samantha M, et al.
Publicado: (2022)

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients
por: Martinez-Paniagua, Melisa, et al.
Publicado: (2015)

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
por: Im, Jin S., et al.
Publicado: (2016)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qguc3np8jqolhfup186tgiodjo